Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Mankind Pharma Ltd indicates a balanced stance on the stock, suggesting that investors should neither aggressively buy nor sell at this juncture. This rating was assigned on 21 May 2026, following a reassessment of the company’s overall profile. The 'Hold' recommendation reflects a moderate outlook, where the stock exhibits both strengths and areas of caution. Investors are advised to maintain their positions while monitoring developments closely.
Here’s How Mankind Pharma Looks Today
As of 02 June 2026, Mankind Pharma Ltd is classified as a midcap company operating within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score currently stands at 50.0, down from 72 previously, which corresponds to the 'Hold' grade. This score encapsulates a comprehensive evaluation of the stock’s quality, valuation, financial trend, and technical indicators.
Quality Assessment
The company’s quality grade is rated as 'good', reflecting robust operational efficiency and management effectiveness. Mankind Pharma demonstrates a high Return on Capital Employed (ROCE) of 20.79%, signalling efficient use of capital to generate profits. Additionally, the company maintains a low Debt to EBITDA ratio of 1.74 times, underscoring its strong ability to service debt and maintain financial stability. Operating profit has grown at an annual rate of 20.15%, indicating healthy long-term growth prospects. These factors collectively contribute to the company’s solid quality profile.
Valuation Considerations
Despite its strong fundamentals, Mankind Pharma is currently considered 'expensive' in terms of valuation. The stock trades at an Enterprise Value to Capital Employed ratio of 4.8, which is higher than average, reflecting a premium pricing relative to its capital base. The company’s ROCE of 13.3% in this context suggests that investors are paying a higher price for the returns generated. The PEG ratio stands at 31.2, indicating that the stock’s price growth may be outpacing earnings growth. While the valuation is fair compared to peers’ historical averages, it warrants caution for value-conscious investors.
Financial Trend Analysis
The financial trend for Mankind Pharma remains positive. The latest quarterly results for March 2026 highlight record operating profit before depreciation, interest, and taxes (PBDIT) of ₹929.88 crores. Operating profit to interest coverage ratio is at a high of 6.56 times, and operating profit to net sales ratio is 27.01%, both reflecting strong profitability and operational efficiency. Over the past year, the stock has delivered a return of -4.26%, while profits have increased by 1.6%, indicating resilience despite market headwinds. Institutional investors hold 24.7% of the stock, signalling confidence from knowledgeable market participants.
Technical Outlook
Technically, the stock is rated as 'mildly bearish'. Recent price movements show a slight decline of 0.39% on the day, with a one-week drop of 4.44%. However, the stock has posted modest gains over the past month (+2.88%), three months (+2.95%), six months (+4.29%), and year-to-date (+5.23%). This mixed technical picture suggests some short-term caution but also underlying support levels that could stabilise the stock price. Investors should watch for confirmation of momentum before making significant trading decisions.
Implications for Investors
The 'Hold' rating implies that Mankind Pharma Ltd currently offers a balanced risk-reward profile. The company’s strong quality metrics and positive financial trends are offset by an expensive valuation and cautious technical signals. For investors, this means maintaining existing positions while awaiting clearer signs of either a sustained upward momentum or a more attractive valuation entry point. The stock’s midcap status and sector exposure to Pharmaceuticals & Biotechnology also suggest it could benefit from sectoral tailwinds, but valuation discipline remains key.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Summary of Key Metrics
As of 02 June 2026, Mankind Pharma Ltd’s stock returns show a mixed performance: a slight negative return over one year (-4.26%) contrasts with positive returns over shorter periods such as one month (+2.88%) and year-to-date (+5.23%). The company’s financial health is underscored by a high ROCE of 20.79%, low leverage, and consistent profit growth. However, valuation metrics such as the Enterprise Value to Capital Employed ratio and PEG ratio suggest the stock is priced at a premium, which tempers enthusiasm.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Mankind Pharma benefits from steady demand and innovation-driven growth. The midcap classification places it in a category with potential for expansion but also volatility. Institutional holdings of 24.7% reflect a significant stake by sophisticated investors, which can provide stability and informed oversight. Market participants should consider sector trends, regulatory developments, and competitive dynamics when evaluating the stock’s prospects.
Conclusion
In conclusion, Mankind Pharma Ltd’s 'Hold' rating by MarketsMOJO as of 21 May 2026 reflects a nuanced view of the company’s current standing. The stock exhibits strong quality and positive financial trends but is tempered by expensive valuation and cautious technical signals. Investors are advised to maintain positions and monitor developments closely, balancing the company’s growth potential against valuation considerations and market conditions.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
